Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interferon-alpha-induced hyperthyroidism: a three-stage evolution from silent thyroiditis towards Graves' disease.

Nathalie Lévy Bohbot1, Jacques Young, Jacques Orgiazzi

  • 1Service d'Endocrinologie, Centre Hospitalier Universitaire de Reims, Hôpital Robert Debré, France.

European Journal of Endocrinology
|February 25, 2006
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Maturity Onset Diabetes of the Young (MODY): French National Diagnosis and Care Protocol (PNDS, Protocole National de Diagnostic et de Soins).

Orphanet journal of rare diseases·2026
Same author

[Metabolic dysfunction-associated steatotic liver diseases: 10 key messages].

La Revue du praticien·2026
Same author

Risk of bone overstimulation in long-term PTH(1-34) therapy for hypoparathyroidism.

European journal of endocrinology·2026
Same author

Use of osilodrostat in a block-and-replace and titration strategy for cushing's syndrome: a position paper by French experts.

Reviews in endocrine & metabolic disorders·2026
Same author

More on Osilodrostat for Bilateral Adrenal Hypercortisolism in Primary Aldosteronism. Reply.

The New England journal of medicine·2026
Same author

Giant cell tumor of the sphenoid bone: a systematic literature review with illustrative cases.

Endocrine-related cancer·2026

Interferon-alpha (IFN-alpha) treatment for hepatitis C can cause autoimmune thyroid disease. Patients may develop silent thyroiditis followed by Graves

Area of Science:

  • Endocrinology
  • Hepatology
  • Immunology

Background:

  • Autoimmune thyroid disease is a known side effect of interferon-alpha (IFN-alpha) therapy.
  • Hepatitis C treatment often involves IFN-alpha and ribavirin.

Observation:

  • Three male patients with hepatitis C developed sequential thyroid conditions during IFN-alpha treatment.
  • Patients experienced destructive thyrotoxicosis (silent thyroiditis) 4-6 months post-treatment initiation.
  • Graves' disease hyperthyroidism emerged 8-11 months after starting IFN-alpha.

Findings:

  • Destructive thyroiditis was characterized by negative anti-TSH receptor antibodies (TSHRAb) and low radionuclide uptake.
  • Graves' disease was confirmed by positive TSHRAb and high scintigraphic uptake.
  • IFN-alpha treatment can induce hyperthyroidism presenting as silent thyroiditis, Graves' disease, or both sequentially.

Related Experiment Videos

Implications:

  • Accurate diagnosis of IFN-alpha-induced thyroid dysfunction is crucial.
  • Repeated thyroid scintiscans and TSHRAb monitoring are essential for correct diagnosis and management.
  • Distinguishing between silent thyroiditis and Graves' disease prevents inappropriate therapeutic decisions.